• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受化疗的非小细胞肺癌患者发生骨相关事件的危险因素。

Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.

作者信息

Sekine Ikuo, Nokihara Hiroshi, Yamamoto Noboru, Kunitoh Hideo, Ohe Yuichiro, Tamura Tomohide

机构信息

Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.

出版信息

Lung Cancer. 2009 Aug;65(2):219-22. doi: 10.1016/j.lungcan.2008.10.026. Epub 2008 Dec 10.

DOI:10.1016/j.lungcan.2008.10.026
PMID:19081161
Abstract

The purpose of this study was to identify the risk factors for skeletal-related events (SREs) in patients with advanced non-small cell lung cancer (NSCLC). SREs were defined as pathologic fractures, spinal cord compression, requirement for radiation therapy, other radiological intervention, or surgery to the bone, and hypercalcemia of malignancy. Time-to-the first SRE and SRE-free survival, and their associations with the patient characteristics were evaluated retrospectively in 642 patients with metastatic NSCLC who received systemic chemotherapy. A total of 118 (18.4%) patients developed SREs during or after the initial chemotherapy. Of these, 107 required radiotherapy to the bone, 5 developed hypercalcemia of malignancy, 3 developed compression fracture of the vertebrae, 2 required surgical treatment of the bone, and 1 underwent radiofrequency ablation therapy to the bone. The first SRE occurred within 12 months in 80 (67.8%) of the 107 patients. The results of multivariate analysis revealed that male sex, performance status (PS) of 2-3 and multiple bone metastases were risk factors for the first SRE, with hazard ratios (HRs) (95% confidence interval [CI]) to the reference of 1.44 (0.98-2.11), 2.21 (0.97-5.03) and 4.43 (2.91-6.76), respectively. SRE-free survival showed a similar trend. The HRs (CI) of male sex, PS of 2 and multiple bone metastases were 1.64 (1.30-2.06), 3.72 (2.31-5.98) and 1.80 (1.40-2.31), respectively. In conclusion, the presence of multiple bone metastases was significantly associated with the development of SRE in patients with advanced NSCLC treated by systemic chemotherapy. Male sex and poor performance status may be additional risk factors for the development of SREs in these patients.

摘要

本研究的目的是确定晚期非小细胞肺癌(NSCLC)患者发生骨相关事件(SREs)的危险因素。SREs被定义为病理性骨折、脊髓压迫、需要进行放射治疗、其他放射学干预或骨手术,以及恶性肿瘤高钙血症。对642例接受全身化疗的转移性NSCLC患者回顾性评估首次发生SRE的时间和无SRE生存期,以及它们与患者特征的关联。共有118例(18.4%)患者在初始化疗期间或之后发生SREs。其中,107例需要进行骨放疗,5例发生恶性肿瘤高钙血症,3例发生椎体压缩性骨折,2例需要进行骨手术治疗,1例接受了骨射频消融治疗。107例患者中有80例(67.8%)在12个月内发生首次SRE。多因素分析结果显示,男性、体能状态(PS)为2 - 3分和多发骨转移是首次发生SRE的危险因素,风险比(HRs)(95%置信区间[CI])相对于参照分别为1.44(0.98 - 2.11)、2.21(0.97 - 5.​​03)和4.43(2.91 - 6.76)。无SRE生存期显示出类似趋势。男性、PS为2分和多发骨转移的HRs(CI)分别为1.64(1.30 - 2.06)、3.72(2.31 - 5.98)和1.80(1.40 - 2.31)。总之,多发骨转移的存在与接受全身化疗的晚期NSCLC患者发生SRE显著相关。男性和体能状态差可能是这些患者发生SRE的额外危险因素。

相似文献

1
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.接受化疗的非小细胞肺癌患者发生骨相关事件的危险因素。
Lung Cancer. 2009 Aug;65(2):219-22. doi: 10.1016/j.lungcan.2008.10.026. Epub 2008 Dec 10.
2
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.肺癌骨转移患者骨相关事件的治疗费用。
Oncology. 2004;67(5-6):390-6. doi: 10.1159/000082923.
3
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.唑来膦酸治疗非小细胞肺癌及其他实体瘤患者骨转移的长期疗效和安全性:一项随机、III期、双盲、安慰剂对照试验
Cancer. 2004 Jun 15;100(12):2613-21. doi: 10.1002/cncr.20308.
4
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.骨转移非小细胞肺癌患者骨骼相关事件的预测因素。
Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3.
5
Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer.术后局部晚期非小细胞肺癌发生脑转移的风险
Lung Cancer. 2009 May;64(2):238-43. doi: 10.1016/j.lungcan.2008.08.012. Epub 2008 Oct 5.
6
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.初诊时发生骨转移的非小细胞肺癌的预后因素。
Lung Cancer. 2012 Sep;77(3):572-7. doi: 10.1016/j.lungcan.2012.05.094. Epub 2012 Jun 4.
7
Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study.非小细胞肺癌脑转移患者颅脑照射后全身化疗的回顾性研究
Lung Cancer. 2009 Mar;63(3):405-9. doi: 10.1016/j.lungcan.2008.06.002. Epub 2008 Jul 14.
8
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.唑来膦酸和锶-89 治疗非小细胞肺癌无症状骨转移患者的临床意义。
Clin Lung Cancer. 2013 May;14(3):254-60. doi: 10.1016/j.cllc.2012.09.001. Epub 2012 Oct 25.
9
Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.对典型临床实践中所见的乳腺癌骨转移患者骨骼并发症对总医疗费用影响的回顾性研究。
J Support Oncol. 2006 Jul-Aug;4(7):341-7.
10
Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.非小细胞肺癌骨转移患者发生骨相关事件(SREs)的危险因素及影响无SRE生存的因素。
Tumour Biol. 2016 Jan;37(1):1131-40. doi: 10.1007/s13277-015-3907-z. Epub 2015 Aug 15.

引用本文的文献

1
Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.实体瘤骨转移患者停用地诺单抗治疗后与骨相关事件相关的危险因素:一种真实世界的机器学习方法。
J Bone Oncol. 2022 Mar 17;34:100423. doi: 10.1016/j.jbo.2022.100423. eCollection 2022 Jun.
2
Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update.非小细胞肺癌中的寡转移疾病:最新进展
Cancers (Basel). 2022 Mar 6;14(5):1350. doi: 10.3390/cancers14051350.
3
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
骨改良药物治疗的非小细胞肺癌患者骨骼相关事件的风险因素。
Support Care Cancer. 2021 Jul;29(7):4081-4088. doi: 10.1007/s00520-020-05880-5. Epub 2021 Jan 6.
4
Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.唑来膦酸治疗非小细胞肺癌骨转移患者骨骼相关事件的风险因素:一项随机临床试验的事后分析。
Support Care Cancer. 2021 Mar;29(3):1629-1633. doi: 10.1007/s00520-020-05665-w. Epub 2020 Aug 3.
5
Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer.非小细胞肺癌骨转移患者的临床特征和预后因素。
J Int Med Res. 2020 May;48(5):300060520925644. doi: 10.1177/0300060520925644.
6
The Impact of Lung Carcinoma Histology on the Frequency of Bone Metastases.肺癌组织学对骨转移频率的影响。
Rev Bras Ortop (Sao Paulo). 2019 Sep;54(5):524-530. doi: 10.1016/j.rbo.2018.02.002. Epub 2019 Sep 19.
7
Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms.神经内分泌肿瘤骨转移的姑息性放射治疗
Adv Radiat Oncol. 2019 Apr 10;4(3):513-519. doi: 10.1016/j.adro.2019.03.014. eCollection 2019 Jul-Sep.
8
PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL.肺癌骨转移所致病理性骨折:危险因素与生存情况
Acta Ortop Bras. 2018;26(6):388-393. doi: 10.1590/1413-785220182606201669.
9
Risk factors for bone metastasis in patients with primary lung cancer: A systematic review.原发性肺癌患者骨转移的危险因素:一项系统综述。
Medicine (Baltimore). 2019 Jan;98(3):e14084. doi: 10.1097/MD.0000000000014084.
10
Lung cancer with bone metastases in the United States: an analysis from the Surveillance, Epidemiologic, and End Results database.美国伴骨转移的肺癌:来自监测、流行病学和最终结果数据库的分析。
Clin Exp Metastasis. 2018 Dec;35(8):753-761. doi: 10.1007/s10585-018-9943-5. Epub 2018 Oct 19.